AstraZeneca reportedly offered about $10 billion to buy Rhythm Pharmaceuticals

AstraZeneca reportedly made a $10 billion offer to buy Rhythm Pharmaceuticals, offering about $124 a share last month, per the Wall Street Journal. The deal would add to AstraZeneca's rare disease treatments; Rhythm specializes in metabolic conditions and severe obesity.

Detected & updated continuously · Source: Nebula